INTEGRA LIFESCIENCES HOLDINGS CORP

For the period ended Sep 30, 2024. Filed Nov 4, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 4, 2024

IART$14.37+7.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 1. Financial Statements

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE INCOME

(Dollars in thousands, except per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Total revenue, net	$380,834	$382,421	$1,167,881	$1,144,534
Costs and expenses:
Cost of goods sold	180,596	164,076	534,892	486,292
Research and development	27,435	26,596	84,167	79,908
Selling, general and administrative	177,193	161,948	538,463	493,513
Intangible asset amortization	3,760	3,208	17,575	9,342
Total costs and expenses	388,984	355,828	1,175,097	1,069,055
Operating (loss) income	(8,150)	26,593	(7,216)	75,479
Interest income	5,049	4,607	15,147	12,653
Interest expense	(19,373)	(13,062)	(51,648)	(37,626)
Other income, net	2,112	471	2,939	1,705
(Loss) income before income taxes	(20,362)	18,609	(40,778)	52,211
(Benefit) provision for income taxes	(9,667)	(888)	(14,399)	4,304
Net (loss) income	$(10,695)	$19,497	$(26,379)	$47,907
Net (loss) income per share
Basic	$(0.14)	$0.24	$(0.34)	$0.59
Diluted	$(0.14)	$0.24	$(0.34)	$0.59
Weighted average common shares outstanding (See Note 13):
Basic	76,448	79,690	77,196	80,842
Diluted	76,448	79,811	77,196	81,112
Comprehensive income (See Note 14)	(16,823)	16,412	(36,126)	$39,387

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.